drugset
drugset / Trial / NCT04380753

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

NCT04380753 ↗

Phase 1 Completed 12 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.

Timeline

Start
2020-04-28
Primary completion
2021-12-31
Completion
2026-02-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotorasib Small molecule — Oral

Indications

No indication recorded.